Why Are LumiraDx Shares Trading Higher Today?

by Vandana Singh, Benzinga Editor

October 20, 2021 3:13 PM | 1 min read |

LumiraDx LMDX has received emergency use approval by India's Central Drugs Standard Control Organisation for its SARS-CoV-2 Antigen test.
The test detects antigen nucleocapsid protein from a nasal swab with results in under 12 minutes from sample application.
The test is available in the U.S. and Europe under Emergency Use Authorization.
The LumiraDx SARS-CoV-2 Antigen test is a microfluidic test run on the LumiraDx point of care Platform, which scales down. It integrates techniques used in laboratory analyzers to provide lab-comparable diagnostic tests on a single point of care instrument.
Related content: Benzinga's Full FDA Calendar.
Price Action: LMDX shares are up 13.20% at $9.54 during the market session on the last check Wednesday.

Posted In: Long Ideas News Health Care FDA Movers Trading Ideas General Briefs COVID-19 Coronavirus Diagnostics why it's moving

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.